匹伐他汀对不稳定性心绞痛患者血清CRP和ET的影响  

Impacts of pitavastatin on serum CRP and ET in patients with unstable angina

作　　者：谢辉[1] 曹薇[1] 符江琳[1] 

机构地区：[1]湖北医药学院附属人民医院心内科,湖北十堰442000

出　　处：《西南国防医药》2017年第8期805-807,共3页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的分析匹伐他汀治疗老年早期不稳定性心绞痛时,患者血清C-反应蛋白(CRP)及内皮素(ET)水平的变化。方法随机选取医院确诊为早期不稳定性心绞痛的老年患者80例,随机分成观察组和对照组各40例,对照组给予基础药物常规治疗,观察组在常规治疗的基础上加用匹伐他汀口服治疗,治疗1个月,比较两组治疗前后血清CRP及ET水平的变化。结果与治疗前比较,两组治疗后血清CRP及ET含量均明显降低(P<0.05),且观察组降低幅度比对照组更大(P<0.05);而两组药物不良反应发生率比较无统计学差异(P>0.05)。结论匹伐他汀用于早期治疗老年性不稳定型心绞痛的临床疗效确切,安全性高,值得临床推广。Objective To analyze the changes in serum C-reactive protein （CRP） and endothelin （ET） levels in the treatment of early unstable angina in senile patients ＂with pitavastatin. MeAods A total of 80 senile patients diagnosed as early unstable angina in our hospital were selected and randomly divided into an obseration group and a control group （n=40, respectively）. The control group was treated with conventional therapy with essential medicine and the observation group was additionally treated with pitavastatin by oral administration for one month. The changes in the serum CRP and ET levels before and after the treatment between the two groups were compared. Results The post-treatment serum CRP and ET content in the two groups decreased significantly （P 〈 0.05）, and the decrease in the observation group was greater than that in the control group （P 〈 0.05）; the incidence of adverse drug reactions between the two groups showed no statistical difference （P 〉 0.05）. Conclusion Pitavastatin has obvious effects and high safety in the treatment of early unstable angina in senile patients, so it is worthy of clinical popularization.

关 键 词：匹伐他汀 不稳定性心绞痛 C-反应蛋白 内皮素 

分 类 号：R541.4[医药卫生—心血管疾病]